| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 47 |
| 1 | PEMETREXED DISODIUM | 28 |
| 2 | PEMETREXED | 25 |
| 3 | NIVOLUMAB | 19 |
| 4 | PACLITAXEL | 19 |
| 5 | BEVACIZUMAB | 16 |
| 6 | IPILIMUMAB | 14 |
| 7 | FULVESTRANT | 12 |
| 8 | RIBOCICLIB | 9 |
| 9 | LORLATINIB | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEMIPLIMAB-RWLC | 4 | 0.0019 |
| 1 | TEBENTAFUSP | 1 | 0.0017 |
| 2 | BEVACIZUMAB-BVZR | 1 | 0.0014 |
| 3 | LORLATINIB | 7 | 0.0009 |
| 4 | PEMETREXED DISODIUM | 28 | 0.0007 |
| 5 | FLURBIPROFEN | 1 | 0.0007 |
| 6 | PRALSETINIB | 1 | 0.0005 |
| 7 | AFATINIB | 3 | 0.0005 |
| 8 | ALECTINIB HYDROCHLORIDE | 3 | 0.0004 |
| 9 | ENFORTUMAB VEDOTIN | 3 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 1 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 7 | 0.0003 |
| 2 | Estrogen Receptor Antagonist [EPC] | 12 | 0.0003 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 14 | 0.0003 |
| 4 | Platinum-based Drug [EPC] | 54 | 0.0002 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 19 | 0.0002 |
| 6 | Microtubule Inhibitor [EPC] | 19 | 0.0001 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 2 | 0.0001 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 17 | 0.0001 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 25 | 0.0001 |